Voices
September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant Immunotherapy – Agenus

September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant Immunotherapy – Agenus

Agenus shared on LinkedIn:

“Missed our September Stakeholder Webcast yesterday?

Watch the replay now

Hear updates on ROBBIN Phase 3 execution, continued physician interest in BOT+BAL, recent clinical publications and the rationale for studying immunotherapy before surgery.”

Agenus

You can also read: Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer

September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant Immunotherapy - Agenus

Agenus Balstilimab BOTBAL botensilimab cancer immunotherapy OncoDaily Oncology ROBBIN Phase 3